DeepMed Research

FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

Recruiting

Conditions: Urothelial Carcinoma
Non-Muscle Invasive Bladder Urothelial Carcinoma
Muscle Invasive Bladder Urothelial Carcinoma

First Posted Date: 2024-05-02

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 92

Registration Number: NCT06396533

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

mychoiceTM Implementation With Medical Oncology Patients

Not Applicable

Recruiting

Conditions: Cancer

Interventions: Behavioral: mychoiceTM

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 200

Registration Number: NCT06222242

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Phase 1

Recruiting

Conditions: Primary Myelofibrosis
Chronic Myelomonocytic Leukemia
Polycythemia Vera
Essential Thrombocytosis
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis

Interventions: Drug: Talazoparib
Drug: pacritinib

First Posted Date: 2024-01-23

Last Posted Date: 2024-05-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT06218628

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)

Phase 2

Withdrawn

Conditions: Metastatic Urothelial Carcinoma

Interventions: Drug: Pembrolizumab (200mg)
Drug: Pembrolizumab (400mg)
Diagnostic Test: Monitoring

First Posted Date: 2023-09-22

Last Posted Date: 2023-11-09

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT06050954

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Phase 2

Recruiting

Conditions: Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma

Interventions: Drug: Enfortumab vedotin
Drug: Pembrolizumab

First Posted Date: 2023-06-28

Last Posted Date: 2024-07-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 70

Registration Number: NCT05923190

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Buprenorphine for Cancer Pain

Phase 4

Recruiting

Conditions: Cancer-Related Pain

Interventions: Drug: Use of buprenorphine with FAO > 30 OME
Behavioral: CPM Rx application use

First Posted Date: 2023-06-18

Last Posted Date: 2023-07-10

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 50

Registration Number: NCT05910190

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Adaptive Radiation for Abdominopelvic Metastases

Phase 1

Recruiting

Conditions: Neoplasm - Soft Tissue Pelvis Malignant Secondary
Malignant Neoplasm of Stomach

Interventions: Radiation: Adaptive Stereotactic Body Radiation

First Posted Date: 2023-05-30

Last Posted Date: 2023-09-21

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 30

Registration Number: NCT05880667

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Phase 2

Recruiting

Conditions: Lung Cancer
Small-cell Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Nab paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Etoposide
Drug: Irinotecan
Drug: Topotecan
Drug: Lurbinectedin

First Posted Date: 2023-04-05

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 280

Registration Number: NCT05800587

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

Phase 2

Recruiting

Conditions: Anemia

Interventions: Drug: Venofer

First Posted Date: 2023-04-05

Last Posted Date: 2025-03-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 34

Registration Number: NCT05800600

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Phase 2

Recruiting

Conditions: Oropharynx Cancer

Interventions: Radiation: Radiation therapy (5 days for 6 weeks)
Radiation: Radiation therapy (5 days for 7 weeks)
Drug: Cisplatin

First Posted Date: 2023-04-05

Last Posted Date: 2024-12-24

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 22

Registration Number: NCT05800574

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy